Feedback
Settings

Settings

Goto Application

4,719,493 results
Offices all Languages en Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C07

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 471,950
1.3030332PROCESS FOR PREPARING DIENE
ES - 27.06.2025
Int.Class C07C 11/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
CACYCLIC OR CARBOCYCLIC COMPOUNDS
11Acyclic unsaturated hydrocarbons
28containing carbon-to-carbon double bonds and carbon-to-carbon triple bonds
 Appl.No 21752652 Applicant Firmenich SA Inventor JACOBY, Denis
2.3030344GLYCERYL TRIS (BETA-HYDROXYBUTYRATE) FOR USE IN TREATING AND PREVENTING NEURONAL TRANSIENT ISCHEMIC ATTACKS
ES - 27.06.2025
Int.Class A61K 31/22
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
21Esters, e.g. nitroglycerine, selenocyanates
215of carboxylic acids
22of acyclic acids, e.g. pravastatin
 Appl.No 19930919 Applicant Neuroenergy Ventures, Inc. Inventor HASHIM, Sami
3.2039866BROAD-SPECTRUM MESSENGER RIBONUCLEIC ACID VACCINE AGAINST CHIKUNGUNYA VIRUS DESIGNED BY OPTIMIZING FULL-LENGTH STRUCTURAL PROTEIN SEQUENCE
NL - 27.06.2025
Int.Class C07K 14/18
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
18Togaviridae, e.g. flavivirus, pestivirus, yellow fever virus, hepatitis C virus, japanese encephalitis virus
 Appl.No 2039866 Applicant Institute of Medical Biology, Chinese Academy of Inventor Shuaiyao Lu
The present invention belongs to the technical field of messenger ribonucleic acid {mRNA} vaccine preparation, and specifically relates to a broad—spectrum mRNA vaccine against Chilrungunya virus {CHECK-') designed by optimizing the full—length structural protein sequence. Specifically, an amino acid sequence of the protein provided by the present invention is shown in SEQ ID HD. 1. The vaccine provided by the present invention has a stronger level of cellular immune response, a higher sustained level of binding antibodies produced after a dose reaches a certain level, and a certain effect on the level of neutralizing antibodies. In a broad—spectrum, the vaccine produced IÜ neutralizing antibodies against pseudoviruses from West Afiican pedigrees, Indian lÜcean pedigrees, and East Central and SouthAfiican pedigrees, with cross—protection.Fig .l
4.3030258ANTI-PRO/LATENT-MYOSTATIN ANTIBODIES AND USES THEREOF
ES - 27.06.2025
Int.Class C07K 16/22
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
22against growth factors
 Appl.No 21170667 Applicant Scholar Rock, Inc. Inventor CARVEN, Gregory, J.
5.20250205685COMPOSITE OXIDE, PREPARATION METHOD FOR COMPOSITE OXIDE, HYDROGENATION CATALYST AND USE THEREOF
US - 26.06.2025
Int.Class B01J 21/06
BPERFORMING OPERATIONS; TRANSPORTING
01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
21Catalysts comprising the elements, oxides or hydroxides of magnesium, boron, aluminium, carbon, silicon, titanium, zirconium or hafnium
06Silicon, titanium, zirconium or hafnium; Oxides or hydroxides thereof
 Appl.No 18850098 Applicant CHINA PETROLEUM & CHEMICAL CORPORATION Inventor Zhou DU

A composite oxide contains 60-95 wt % of aluminum oxide and 5-40 wt % of titanium dioxide. The specific surface area of the composite oxide determined by means of BET method is expressed as X m2/g. The average pore diameter of the composite oxide determined by means of nitrogen adsorption isothermal curve method is expressed as Y nm. The ratio of X to Y is 5-30. By means of the determination of X-ray diffraction method, titanium dioxide in an anatase crystalline phase in the composite oxide accounts for 95-100 wt % of the total titanium dioxide. X is in the range of 50-200, preferably X is in the range of 60-180, more preferably in the range of 80-150, and Y is in the range of 5-25 nm. A hydrogenation catalyst that contains the composite oxide shows a high vinyl acetylene conversion rate and a high 1,3-butadiene selectivity.

6.20250206744IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS
US - 26.06.2025
Int.Class C07D 487/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
487Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/-C07D477/183
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
 Appl.No 18973307 Applicant Janssen Pharmaceutica NV Inventor Steven D. Goldberg

The present application discloses compounds having the following formula:

embedded image

or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, and R4 are defined in the specification, as well as methods of making and using the compounds disclosed herein for treating or ameliorating an IL-17 mediated syndrome, disorder and/or disease.

7.20250206770CAP COMPOUNDS AND RNAS COMPRISING THE SAME
US - 26.06.2025
Int.Class C07H 21/02
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
21Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
02with ribosyl as saccharide radical
 Appl.No 18990530 Applicant Helix Nanotechnologies Inc Inventor Nikhil Dhar

Disclosed herein are 5′ cap structures comprising a 2′-O-acetyl ribose. Also provided herein are polyribonucleotides comprising a 5′ cap structure disclosed herein and compositions comprising the same as well as methods of making and using the same.

8.20250206775METHODS OF ISOLATING POLYPEPTIDES
US - 26.06.2025
Int.Class C07K 1/36
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
1General processes for the preparation of peptides
14Extraction; Separation; Purification
36by a combination of two or more processes of different types
 Appl.No 18848359 Applicant BRISTOL-MYERS SQUIBB COMPANY Inventor Elizabeth BIGELOW

The present disclosure is directed methods of isolating and/or purifying a species of a protein, comprising contacting a mixture comprising the species and one or more impurities with two or more chromatography columns in a continuous operation mode. In some aspects, the species of the protein is a charge variant.

9.20250206788CURCUMIN-PEPTIDE CONJUGATES AND FORMULATIONS THEREOF
US - 26.06.2025
Int.Class C07K 14/47
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
46from vertebrates
47from mammals
 Appl.No 19074778 Applicant John Chancey Inventor Adam J. PAYNE

Disclosed here are compositions comprising a curcuminoid-N-acetyl cysteine (NAC) complex. Also disclosed are methods of preparing a curcuminoid-N-acetyl cysteine (NAC) complex. Also disclosed are methods of treating a subject, the method comprising identifying a subject in need of treatment of a curcumin-related disorder, and administering to the subject a therapeutic composition comprising a curcuminoid-N-acetyl cysteine (NAC) complex as described. Also disclosed are therapeutic compositions comprising a curcuminoid-N-acetyl cysteine (NAC) complex as described and a pharmaceutically acceptable excipient, diluent, or carrier.

10.20250206817METHODS OF MANUFACTURING DIMERIC ANTIBODIES
US - 26.06.2025
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
 Appl.No 18807097 Applicant Medicovestor, Inc. Inventor Seah Lim

This disclosure relates to dimeric immunotherapeutics that comprise two IgGs that are crosslinked with a disulfide bond. The two IgGs may be chimeras of two different heavy chains, in which one heavy chain includes a cysteine mutation that forms the disulfide bond, and the other heavy chain lacks the cysteine mutation. The presence of a cysteine mutation in only one of the heavy chains of an IgG avoids two disulfide bonds between the two IgGs, which increases the accessible orientations between the two crosslinked IgGs, and also avoids the formation of trimers and higher-order oligomers.

# -